Introduction Plasma proteins affect biological processes and are common drug targets but
their role in the development of Alzheimer's disease and related dementias remains unclear …

Background Plasma amyloid-β (Aβ)(Aβ 42, Aβ 40, and Aβ 42/Aβ 40), biomarkers of the
Alzheimer's form of dementia, are under consideration for clinical use. The associations of …

A blood-based protein biomarker, or set of protein biomarkers, that could predict onset and
progression of Alzheimer's disease (AD) would have great utility; potentially clinically, but …

Introduction This study sought to discover and replicate plasma proteomic biomarkers
relating to Alzheimer's disease (AD) including both the “ATN”(amyloid/tau …

Introduction Plasma proteins have been widely studied as candidate biomarkers to predict
brain amyloid deposition to increase recruitment efficiency in secondary prevention clinical …

Objective Few studies have comprehensively examined how health and disease risk
influence Alzheimer's disease (AD) biomarkers. The present study examined the association …

Background Plasma amyloid-β (Aβ) peptide levels have been examined as a low-cost
accessible marker for risk of incident Alzheimer's disease (AD) and dementia, but results …

Introduction Biomarker discovery of dementia and cognitive impairment is important to
gather insight into mechanisms underlying the pathogenesis of these conditions. Methods In …

Background: Four previously reported studies have tested for association of blood proteins
with neocortical amyloid-burden (NAB). If shown to be robust, these proteins could have …

Introduction Plasma biomarkers—cost effective, non‐invasive indicators of Alzheimer's
disease (AD) and related disorders (ADRD)—have largely been studied in clinical research …